Keywords
leczenie systemowe
późne objawy uboczne
How to Cite
Abstract
W ostatnich latach znacząco poprawiły się wyniki leczenia raka piersi. W dużej mierze związane jest to ze stosowaniem uzupełniającego leczenia systemowego.
Optymalna chemioterapia i immunoterapia oraz kompleksowa hormonoterapia przyczyniły się do wydłużenia czasu przeżycia całkowitego i czasu wolnego od choroby, jednak leczenie nieuchronnie wiąże się z występowaniem działań niepożądanych, które mogą wpływać na jakość życia chorych.
Wczesne działania niepożądane leczenia systemowego ustępują maksymalnie do 6 miesięcy od zakończenia terapii. Późne objawy uboczne mogą utrzymywać się do końca życia pacjentów, a metody ich leczenia są często niesatysfakcjonujące.
References
Didkowska J, Wojciechowska U, Nowotwory złośliwe w Polsce w 2013 roku. Centrum Onkologii – Instytut im. M. Skłodowskiej-Curie, Warszawa 2015.
Yeh E, Tong A, Lenihan D, Yusuf S, Swafford J, Champion C, et al. Cardiovascular complications of cancer therapy: Diagnosis, pathogenesis, and management. Circulation 2004; 109:3122-3131
Lefrak E, Pitha J, Rosenheim S, Gottlieb J: A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973; 32:302-314
Swain S, Whaley F, Ewer M, Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003 Jun 1;97(11):2869-79
Perez D, Harvey V, Robinson B, Atkinson C, Dady P, Kirk A et al. A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer. J Clin Oncol. 1991 Dec;9(12):2148-52
Ryberg M, Nielsen D, Skovsgaard T, Hansen J, Jensen B, Dombernowsky P. Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J Clin Oncol. 1998 Nov;16(11):3502-8
Tahover E, Segal A, Isacson R, Rosengarten O, Grenader T, Gips M et al. Dexrazoxane added to doxorubicin-based adjuvant chemotherapy of breast cancer: a retrospective cohort study with a comparative analysis of toxicity and survival. Anicancer Drugs. 2017 Aug;28(7):787-794.
Hrdina R, Gersl V, Klimtova I, Simunek T, Machackova J, Adamcova M. Anthracycline-induced cardiotoxicity. Acta Medica (Hradec Kralove). 2000;43(3):75-82
Gianni L, Munzone E, Capri G, Fulfaro F, Tarenzi E, Villani F et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol. 1995 Nov;13(11):2688-99
Gianni L, Viganò L, Locatelli A, Capri G, Giani A, Tarenzi E et al. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol. 1997 May;15(5):1906-15.
Olson R, Mushlin P. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J. 1990 Oct;4(13):3076-86.
Cameron D, Piccart-Gebhart M, Gelber R, Procter M, Goldhirsch A, de Azambuja E et al. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017 Mar 25;389(10075):1195-1205.
Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011 Oct 6;365(14):1273-83.
Perez E, Romond E, Suman V, Jeong J, Sledge G, Geyer C Jr et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014 Nov 20;32(33):3744-52.
Seidman A, Hudis C, Pierri M, Shak S, Paton V, Ashby M et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002 Mar 1;20(5):1215-21.
Curigliano G, Cardinale D, Suter T,Plataniotis G, de Azambuja E, Sandri M et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice guidelines. Ann Oncol, 2012; 23: 155-66.
Lenihan D, Esteva F. Multidisciplinary strategy for managing cardiovascular risks when treating patients with early breast cancer. Oncologist. 2008 Dec;13(12):1224-34.
Buzdar A, Howell A, Cuzick J, Wale C, Distler W, Hoctin-Boes G et al. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol. 2006 Aug;7(8):633-43.
Sparano J, Wang M, Martino S, Jones V, Perez E, Saphner T et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008 Apr 17;358(16):1663-71.
Schneider B, Zhao F, Wang M, Stearns V, Martino S, Jones V, Perez E et al. Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer. J Clin Oncol. 2012 Sep 1;30(25):3051-7.
Kim P, Johnson C. Chemotherapy-induced peripheral neuropathy: a review of recent findings. Curr Opin Anaesthesiol. 2017 Oct;30(5):570-576.
Meattini I, Desideri I, Francolini G, Vannini A, Perna M, Garlatti P et al. Systemic therapies and cognitive impairment for breast cancer: an overview of the current literature. Med Oncol. 2017 May;34(5):74
Chan R, McCarthy A, Devenish J, Sullivan K, Chan A. Systematic review of pharmacologic and non-pharmacologic interventions to manage cognitive alterations after chemotherapy for breast cancer. Eur J Cancer 2015 Mar;51(4):437-50
Phillips K, Regan M, Ribi K, Francis P, Puglisi F, Bellet M et al. Adjuvant ovarian function suppression and cognitive function in women with breast cancer. Br J Cancer. 2016 Apr 26;114(9):956-64
Asbjørnsen G, Godal HC, Myhre K., Acute myelogenous leukemia after cytostatic therapy of breast cancer. Tidsskr Nor Laegeforen. 1981 Feb 28;101(6):387-8. Norwegian
Smith R. Risk for the development of treatment-related acute myelocytic leukemia and myelodysplastic syndrome among patients with breast cancer: review of the literature and the National Surgical Adjuvant Breast and Bowel Project experience. Clin Breast Cancer. 2003 Oct;4(4):273-9. Review.
Wolff A, Blackford A, Visvanathan K, Rugo H, Moy B, Goldstein L et al. Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience. J Clin Oncol 2015 Feb 1;33(4):340-8
Petrek J, Naughton M, Case L, Paskett E, Naftalis E, Singletary S et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol 2006 Mar 1;24(7):1045-51
Del Mastro L, Boni L, Michelotti A, Gamucci T, Olmeo N, Gori S et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial.,JAMA 2011 Jul 20;306(3):269-76.
Munhoz R, Pereira A, Sasse A, Hoff P, Traina T, Hudis C et al. Gonadotropin-Releasing Hormone Agonists for Ovarian Function Preservation in Premenopausal Women Undergoing Chemotherapy for Early-Stage Breast Cancer: A Systematic Review and Meta-analysis. JAMA Oncol. 2016 Jan;2(1):65-73
Hadji P. Guidelines for Osteoprotection in Breast Cancer Patients on an Aromatase Inhibitor, Breast Care 2010;5:290–296
Hong A, Kim J, Lee K, Kim T, Im S, Kim T et al. Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer. Osteoporos Int. 2017 Apr;28(4):1413-1422
Dhesy-Thind S, Fletcher G, Blanchette P, Clemons M, Dillmon M, Frank E et al. Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017 Jun 20;35(18):2062-2081
Schmidt M, Wiskemann J, Steindorf K. Quality of life, problems, and needs of disease-free breast cancer survivors 5 years after diagnosis. Qual Life Res. 2018 May 8.